Most Read Articles
Pearl Toh, 19 Jan 2021
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.

Product Highlight - Emgality

01 Dec 2020
More migraine-headache-free days.1 Rapid onset and sustained responses.2,3

The only agent with pre-specified 50%/75%/100% response rates among the class2
Rapid onset at Week 1 and sustained response through Month 62,3
Consistently maintains efficacy from week to week between monthly dosing4
Well-tolerated with low discontinuation rates comparable to placebo5
The loading dose for Emgality gives patients a bold start to treatment that won’t require titration or dose adjustments2


References:
1. Skljarevski V, et al. Cephalalgia. 2018;38(8):1442-1454.
2. Emgality Prescribing Information Hong Kong.
3. Detke HC, Millen BA, Zhang Q, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache. 2019;60(2):348-359.
4. Samaan K, Pozo-Rosich P, Nicholson R, Rathmann S, Pearlman E. Consistency of galcanezumab efficacy throughout a month over time. IHC 2019 Late Breaking Abstracts. Cephalalgia. 2019;39(IS):358-427. 5. Bangs et al. BMC Neurology (2020) 20:25.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 19 Jan 2021
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.